Skip Navigation
Skip to contents

Immune Netw.  2013 Aug;13(4):157-162. 10.4110/in.2013.13.4.157.

Targeted Delivery of VP1 Antigen of Foot-and-mouth Disease Virus to M Cells Enhances the Antigen-specific Systemic and Mucosal Immune Response

Affiliations
  • 1Department of Molecular Biology, Interdisciplinary Program of Bioactive Materials, and Institute for Molecular Biology and Genetics, Chonbuk National University, Jeonju 561-756, Korea. yongsuk@jbnu.ac.kr

Abstract

Application of vaccine materials through oral mucosal route confers great economical advantage in animal farming industry due to much less vaccination cost compared with that of injection-based vaccination. In particular, oral administration of recombinant protein antigen against foot-and-mouth disease virus (FMDV) is an ideal strategy because it is safe from FMDV transmission during vaccine production and can induce antigen-specific immune response in mucosal compartments, where FMDV infection has been initiated, which is hardly achievable through parenteral immunization. Given that effective delivery of vaccine materials into immune inductive sites is prerequisite for effective oral mucosal vaccination, M cell-targeting strategy is crucial in successful vaccination since M cells are main gateway for luminal antigen influx into mucosal lymphoid tissue. Here, we applied previously identified M cell-targeting ligand Co1 to VP1 of FMDV in order to test the possible oral mucosal vaccination against FMDV infection. M cell-targeting ligand Co1-conjugated VP1 interacted efficiently with M cells of Peyer's patch. In addition, oral administration of ligand-conjugated VP1 enhanced the induction of VP1-specific IgG and IgA responses in systemic and mucosal compartments, respectively, in comparison with those from oral administration of VP1 alone. In addition, the enhanced VP1-specific immune response was found to be due to antigen-specific Th2-type cytokine production. Collectively, it is suggested that the M cell-targeting strategy could be applied to develop efficient oral mucosal vaccine against FMDV infection.

Keyword

Foot-and-mouth disease virus; M cell; Mucosal immunity; Systemic immunity

MeSH Terms

Administration, Oral
Animals
Foot-and-Mouth Disease
Foot-and-Mouth Disease Virus
Imidazoles
Immunity, Mucosal
Immunization
Immunoglobulin A
Immunoglobulin G
Lymphoid Tissue
Nitro Compounds
Phenobarbital
Vaccination
Imidazoles
Immunoglobulin A
Immunoglobulin G
Nitro Compounds
Phenobarbital
Full Text Links
  • IN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2026 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr